Chris Ryan

The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.

Sintilimab plus neoadjuvant chemoradiotherapy yielded a pCR rate of 60% vs 13% from sintilimab plus chemotherapy in patients with locally advanced ESCC.

The CheckMate 649 trial found that nivolumab plus chemotherapy lead to a median OS of 14.3 months vs 10.3 months for chemotherapy alone in several gastrointestinal cancers.

Data from the EMBER-3 trial showed improved progression-free survival with imlunestrant with or without abemaciclib vs SOC in ER+/HER2– breast cancer.

For patients with acute lymphoblastic leukemia and mantle cell leukemia, lymphodepletion then brexu-cel show positive efficacy and safety outcomes.

Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.

Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.

A pembrolizumab regimen for patients with early-stage triple-negative breast cancer yielded improved overall survival.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.

The Melanoma Research Alliance mourns the passing of Jeffrey S. Weber, MD, PhD, a pioneer in developing immunotherapy for patients with melanoma.

“These data support the development of fianlimab plus cemiplimab combination therapy for patients with metastatic ccRCC,” said Miso Kim, MD, PhD.

Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.

Treatment with zanubrutinib (Brukinsa) was found to have cost savings and quality-adjusted life year benefits compared with acalabrutinib (Calquence) in patients with B-cell malignancies.

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.

Osimertinib may become a new standard of care for those with EGFR-mutant NSCLC, according to Suresh S. Ramalingam, MD, FACP, FASCO.

Subgroup findings suggest a PFS benefit with the addition of encorafenib/binimetinib in patients with liver metastases.

Rates of HPV-related cancers may be decreased in patients under 40 have received an HPV vaccine.

A phase 1b evaluating NXP800 in platinum-resistant ARID1A-mutated ovarian cancer is open for enrollment in the United Kingdom and the United States.

Study finds social determinants of health linked to variations in cervical cancer rates.

Data from the INTERLACE trial support induction chemotherapy prior to chemoradiation as a potential standard in locally advanced cervical cancer.

The phase 2 TROPiCS-03 trial helped elicit responses and disease control in patients with extensive-stage small cell lung cancer who received second-line sacituzumab govitecan.

Findings from the phase 2 GMMG-CONCEPT trial suggest that elevated lactate dehydrogenase levels correlated with worse survival in patients with newly diagnosed, high-risk multiple myeloma.

Adding pembrolizumab to chemotherapy shows little increase in adverse effects among patients with metastatic nonsquamous non–small cell lung cancer in the phase 3 KEYNOTE-789 trial.

Ciltacabtagene autoleucel may become a new standard of care for patients with lenalidomide-refractory myeloma after first relapse, according to an expert from the Medical College of Wisconsin in Milwaukee.

For the pooled analysis, investigators evaluated the efficacy and safety of bispecific antibody elranatamab in patients with relapsed/refractory multiple myeloma enrolled in 1 of the 4 MagnetisMM trials who received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 monoclonal antibody, and 1 BCMA-directed ADC and/or CAR T-cell therapy.

ADAURA included patients at least 18 years of age with completely resected stage IB to IIIA nonsquamous NSCLC who harbored EGFR exon 19 deletions or exon 21 L858R mutations.

Pembrolizumab plus chemotherapy with or without bevacizumab yields a survival benefit in PD-L1 positive patients with cervical cancer in the phase 3 KEYNOTE-826 trial.

Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.